Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
Status: Enrolling
Updated:  12/31/1969
Oregon Medical Research Center, PC
153
mi
from 98109
Portland, OR
A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
Status: Enrolling
Updated: 12/31/1969
Oregon Medical Research Center, PC
153
mi
from 98109
Portland, OR
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
Status: Enrolling
Updated:  12/31/1969
Dermatology and Skin Surgery Center
2349
mi
from 98109
Exton, PA
A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
Status: Enrolling
Updated: 12/31/1969
Dermatology and Skin Surgery Center
2349
mi
from 98109
Exton, PA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
Status: Enrolling
Updated:  12/31/1969
University of Utah MidValley Dematology
707
mi
from 98109
Murray, UT
A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
Status: Enrolling
Updated: 12/31/1969
University of Utah MidValley Dematology
707
mi
from 98109
Murray, UT
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
Status: Enrolling
Updated:  12/31/1969
MultiCare Tacoma General Hospital
40
mi
from 98109
Tacoma, WA
A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
Status: Enrolling
Updated: 12/31/1969
MultiCare Tacoma General Hospital
40
mi
from 98109
Tacoma, WA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
Status: Enrolling
Updated:  12/31/1969
Gemeinschaftspraxis Mahlow
mi
from 98109
Mahlow,
A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
Status: Enrolling
Updated: 12/31/1969
Gemeinschaftspraxis Mahlow
mi
from 98109
Mahlow,
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Advanced Research Associates /ID# 204335
mi
from 98109
Glendale, AZ
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Advanced Research Associates /ID# 204335
mi
from 98109
Glendale, AZ
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Alliance Dermatology and MOHs /ID# 204336
mi
from 98109
Phoenix, AZ
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Alliance Dermatology and MOHs /ID# 204336
mi
from 98109
Phoenix, AZ
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Bakersfield Derma & Skin Cance /ID# 202115
mi
from 98109
Bakersfield, CA
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Bakersfield Derma & Skin Cance /ID# 202115
mi
from 98109
Bakersfield, CA
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Center for Dermatology Clin Res /ID# 202116
mi
from 98109
Fremont, CA
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Center for Dermatology Clin Res /ID# 202116
mi
from 98109
Fremont, CA
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Dermatology Res. Assoc., CA /ID# 202170
mi
from 98109
Los Angeles, CA
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Dermatology Res. Assoc., CA /ID# 202170
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
UC Davis, Dermatology /ID# 202263
mi
from 98109
Sacramento, CA
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
UC Davis, Dermatology /ID# 202263
mi
from 98109
Sacramento, CA
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Medderm Associates /ID# 202162
mi
from 98109
San Diego, CA
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Medderm Associates /ID# 202162
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Sullivan Dermatology /ID# 202177
mi
from 98109
North Miami Beach, FL
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Sullivan Dermatology /ID# 202177
mi
from 98109
North Miami Beach, FL
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Renstar Medical Research /ID# 202113
mi
from 98109
Ocala, FL
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Renstar Medical Research /ID# 202113
mi
from 98109
Ocala, FL
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Progressive Medical Research /ID# 202183
mi
from 98109
Port Orange, FL
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Progressive Medical Research /ID# 202183
mi
from 98109
Port Orange, FL
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Integrated Clinical Research LLC /ID# 202152
mi
from 98109
West Palm Beach, FL
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Integrated Clinical Research LLC /ID# 202152
mi
from 98109
West Palm Beach, FL
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Dermatology Specialists Resear /ID# 202145
mi
from 98109
Louisville, KY
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Dermatology Specialists Resear /ID# 202145
mi
from 98109
Louisville, KY
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
ORA Clinical Res & Development /ID# 204342
mi
from 98109
Andover, MA
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
ORA Clinical Res & Development /ID# 204342
mi
from 98109
Andover, MA
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Med Ctr /ID# 204340
mi
from 98109
Boston, MA
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Med Ctr /ID# 204340
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Minnesota Clinical Study Center /ID# 202369
mi
from 98109
Fridley, MN
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Minnesota Clinical Study Center /ID# 202369
mi
from 98109
Fridley, MN
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Central Dermatology, PC /ID# 202156
mi
from 98109
Saint Louis, MO
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Central Dermatology, PC /ID# 202156
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Psoriasis Treatment Ctr NJ /ID# 202107
mi
from 98109
East Windsor, NJ
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Psoriasis Treatment Ctr NJ /ID# 202107
mi
from 98109
East Windsor, NJ
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Oregon Derm & Res. Ctr /ID# 201652
mi
from 98109
Portland, OR
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Oregon Derm & Res. Ctr /ID# 201652
mi
from 98109
Portland, OR
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Oregon Medical Res Center PC /ID# 201651
mi
from 98109
Portland, OR
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Oregon Medical Res Center PC /ID# 201651
mi
from 98109
Portland, OR
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Partners, LLC /ID# 201736
mi
from 98109
Johnston, RI
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Partners, LLC /ID# 201736
mi
from 98109
Johnston, RI
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Center for Clinical Studies - Houston (Binz) /ID# 202178
mi
from 98109
Houston, TX
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Center for Clinical Studies - Houston (Binz) /ID# 202178
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Progressive Clinical Research /ID# 202155
mi
from 98109
San Antonio, TX
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Progressive Clinical Research /ID# 202155
mi
from 98109
San Antonio, TX
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Center for Clinical Studies - Webster TX /ID# 202154
mi
from 98109
Webster, TX
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Center for Clinical Studies - Webster TX /ID# 202154
mi
from 98109
Webster, TX
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
University of Utah /ID# 204035
mi
from 98109
Salt Lake City, UT
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
University of Utah /ID# 204035
mi
from 98109
Salt Lake City, UT
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Froedtert Mem Lutheran Hosp /ID# 204896
mi
from 98109
Milwaukee, WI
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Froedtert Mem Lutheran Hosp /ID# 204896
mi
from 98109
Milwaukee, WI
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Dermatology and Skin Cancer Specialists, LLC /ID# 203938
mi
from 98109
Rockville, MD
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Dermatology and Skin Cancer Specialists, LLC /ID# 203938
mi
from 98109
Rockville, MD
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
UConn Health /ID# 201745
mi
from 98109
Farmington, CT
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
UConn Health /ID# 201745
mi
from 98109
Farmington, CT
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Synexus Research Cincinnati /ID# 202161
mi
from 98109
Cincinnati, OH
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Synexus Research Cincinnati /ID# 202161
mi
from 98109
Cincinnati, OH
Click here to add this to my saved trials
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Institute for Skin Advancement /ID# 203054
mi
from 98109
Calgary,
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Institute for Skin Advancement /ID# 203054
mi
from 98109
Calgary,
Click here to add this to my saved trials
Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis
A Randomized, Double-blind, Placebo- and Active Controlled Multicenter Trial to Demonstrate Efficacy of Subcutaneous Secukinumab Compared to Placebo and Etanercept (in a Single-blinded Arm) After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, and Long-term Efficacy in Subjects From 6 to Less Than 18 Years of Age With Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis
1786
mi
from 98109
San Antonio, TX
Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis
A Randomized, Double-blind, Placebo- and Active Controlled Multicenter Trial to Demonstrate Efficacy of Subcutaneous Secukinumab Compared to Placebo and Etanercept (in a Single-blinded Arm) After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, and Long-term Efficacy in Subjects From 6 to Less Than 18 Years of Age With Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis
1786
mi
from 98109
San Antonio, TX
Click here to add this to my saved trials
Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis
A Randomized, Double-blind, Placebo- and Active Controlled Multicenter Trial to Demonstrate Efficacy of Subcutaneous Secukinumab Compared to Placebo and Etanercept (in a Single-blinded Arm) After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, and Long-term Efficacy in Subjects From 6 to Less Than 18 Years of Age With Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
4933
mi
from 98109
Bruxelles,
Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis
A Randomized, Double-blind, Placebo- and Active Controlled Multicenter Trial to Demonstrate Efficacy of Subcutaneous Secukinumab Compared to Placebo and Etanercept (in a Single-blinded Arm) After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, and Long-term Efficacy in Subjects From 6 to Less Than 18 Years of Age With Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
4933
mi
from 98109
Bruxelles,
Click here to add this to my saved trials
Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis
A Randomized, Double-blind, Placebo- and Active Controlled Multicenter Trial to Demonstrate Efficacy of Subcutaneous Secukinumab Compared to Placebo and Etanercept (in a Single-blinded Arm) After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, and Long-term Efficacy in Subjects From 6 to Less Than 18 Years of Age With Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigational Site
2521
mi
from 98109
Tampa, FL
Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis
A Randomized, Double-blind, Placebo- and Active Controlled Multicenter Trial to Demonstrate Efficacy of Subcutaneous Secukinumab Compared to Placebo and Etanercept (in a Single-blinded Arm) After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, and Long-term Efficacy in Subjects From 6 to Less Than 18 Years of Age With Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigational Site
2521
mi
from 98109
Tampa, FL
Click here to add this to my saved trials
Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis
A Randomized, Double-blind, Placebo- and Active Controlled Multicenter Trial to Demonstrate Efficacy of Subcutaneous Secukinumab Compared to Placebo and Etanercept (in a Single-blinded Arm) After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, and Long-term Efficacy in Subjects From 6 to Less Than 18 Years of Age With Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2428
mi
from 98109
Norfolk, VA
Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis
A Randomized, Double-blind, Placebo- and Active Controlled Multicenter Trial to Demonstrate Efficacy of Subcutaneous Secukinumab Compared to Placebo and Etanercept (in a Single-blinded Arm) After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, and Long-term Efficacy in Subjects From 6 to Less Than 18 Years of Age With Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2428
mi
from 98109
Norfolk, VA
Click here to add this to my saved trials
Clinical vs. Anecdotal Evidence - Pediatric Atopic Dermatitis
Assessing Caregiver's Confidence in the Use of Topical Corticosteroids for a Child's Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Wake Forest Baptist Medical Center
2275
mi
from 98109
Winston-Salem, NC
Clinical vs. Anecdotal Evidence - Pediatric Atopic Dermatitis
Assessing Caregiver's Confidence in the Use of Topical Corticosteroids for a Child's Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Wake Forest Baptist Medical Center
2275
mi
from 98109
Winston-Salem, NC
Click here to add this to my saved trials
Scratch and Sleep Quantification in Atopic Dermatitis
Quantification of Scratch and Sleep in Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
University of Rochester
2161
mi
from 98109
Rochester, NY
Scratch and Sleep Quantification in Atopic Dermatitis
Quantification of Scratch and Sleep in Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
University of Rochester
2161
mi
from 98109
Rochester, NY
Click here to add this to my saved trials
Effects of Capsaicin on the Structure, Distribution, and Function of Cutaneous Small Nerve Fibers in Psoriatic Skin
Effects of Capsaicin on the Structure, Distribution, and Function of Cutaneous Small Nerve Fibers in Psoriatic Skin
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences, Dermatology
2279
mi
from 98109
Winston-Salem, NC
Effects of Capsaicin on the Structure, Distribution, and Function of Cutaneous Small Nerve Fibers in Psoriatic Skin
Effects of Capsaicin on the Structure, Distribution, and Function of Cutaneous Small Nerve Fibers in Psoriatic Skin
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences, Dermatology
2279
mi
from 98109
Winston-Salem, NC
Click here to add this to my saved trials
Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study
An Open-Label, First-in-human, Safety and Pharmacokinetic Study of 1-Month Sustained-Release Injectable Tacrolimus in Healthy Subjects
Status: Enrolling
Updated:  12/31/1969
Worldwide Clinical Trials
1783
mi
from 98109
San Antonio, TX
Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study
An Open-Label, First-in-human, Safety and Pharmacokinetic Study of 1-Month Sustained-Release Injectable Tacrolimus in Healthy Subjects
Status: Enrolling
Updated: 12/31/1969
Worldwide Clinical Trials
1783
mi
from 98109
San Antonio, TX
Click here to add this to my saved trials
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Arcutis Clinical Site 35
958
mi
from 98109
Beverly Hills, CA
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Arcutis Clinical Site 35
958
mi
from 98109
Beverly Hills, CA
Click here to add this to my saved trials
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Arcutis Clinical Site 29
946
mi
from 98109
Northridge, CA
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Arcutis Clinical Site 29
946
mi
from 98109
Northridge, CA
Click here to add this to my saved trials
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Arcutis Clinical Site 28
1065
mi
from 98109
San Diego, CA
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Arcutis Clinical Site 28
1065
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Arcutis Clinical Site 27
961
mi
from 98109
Santa Monica, CA
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Arcutis Clinical Site 27
961
mi
from 98109
Santa Monica, CA
Click here to add this to my saved trials
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Arcutis Clinical Site 12
2731
mi
from 98109
Miami, FL
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Arcutis Clinical Site 12
2731
mi
from 98109
Miami, FL
Click here to add this to my saved trials
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Arcutis Clinical Site 16
2540
mi
from 98109
Sanford, FL
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Arcutis Clinical Site 16
2540
mi
from 98109
Sanford, FL
Click here to add this to my saved trials
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Arcutis Clinical Site 21
1939
mi
from 98109
Louisville, KY
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Arcutis Clinical Site 21
1939
mi
from 98109
Louisville, KY
Click here to add this to my saved trials
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Arcutis Clinical Site 34
mi
from 98109
Clinton Township, MI
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Arcutis Clinical Site 34
mi
from 98109
Clinton Township, MI
Click here to add this to my saved trials